Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (111-120 of 607) with videos related to

Pageof 61
Sort By:
Seminars in Arthritis and Rheumatism|January 20, 2024
Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trialElana J Bernstein, Christopher P Denton, Suiyuan Huang, et al.
Microvascular Research|July 5, 2019
Sidestream Dark Field (SDF) imaging of oral microcirculation in the assessment of systemic sclerosisM Sha, M Griffin, C P Denton, et al.
Rheumatology (Oxford, England)|June 22, 2012
Sustained improvement of diffuse systemic sclerosis following human cytomegalovirus infection offers insight into pathogenesis and therapyPia Moinzadeh, Korsa Khan, Voon H Ong, et al.
Brain Research|March 19, 1984
The binding of human IgM paraprotein from cases of polyneuropathy associated with benign monoclonal gammopathy to specific neurons of the rodent brainC P Denton, N A Gregson, S Leibowitz, et al.
Clinical and Experimental Rheumatology|October 3, 2009
Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?A Pakozdi, H Wilson, C M Black, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a reviewAaron Tan, Christopher P Denton, Dimitri P Mikhailidis, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trialsDavid Roofeh, Oliver Distler, Yannick Allanore, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Comparing paediatric- and adult-onset linear morphoea in a large tertiary-referral scleroderma centreAmanda M Saracino, Christina George, Svetlana I Nihtyanova, et al.
International Journal of Molecular Sciences|April 28, 2023
Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in RatsGöran Tornling, Rohit Batta, Dan Salvail, et al.
BMJ Case Reports|March 12, 2018
The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toesKiran Dhaliwal, Michelle Griffin, Christopher P Denton, et al.
Pageof 61

Showing results (111-120 of 607) with videos related to

Sort By:
Pageof 61
Seminars in Arthritis and Rheumatism|January 20, 2024
Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trialElana J Bernstein, Christopher P Denton, Suiyuan Huang, et al.
Microvascular Research|July 5, 2019
Sidestream Dark Field (SDF) imaging of oral microcirculation in the assessment of systemic sclerosisM Sha, M Griffin, C P Denton, et al.
Rheumatology (Oxford, England)|June 22, 2012
Sustained improvement of diffuse systemic sclerosis following human cytomegalovirus infection offers insight into pathogenesis and therapyPia Moinzadeh, Korsa Khan, Voon H Ong, et al.
Brain Research|March 19, 1984
The binding of human IgM paraprotein from cases of polyneuropathy associated with benign monoclonal gammopathy to specific neurons of the rodent brainC P Denton, N A Gregson, S Leibowitz, et al.
Clinical and Experimental Rheumatology|October 3, 2009
Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?A Pakozdi, H Wilson, C M Black, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a reviewAaron Tan, Christopher P Denton, Dimitri P Mikhailidis, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trialsDavid Roofeh, Oliver Distler, Yannick Allanore, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Comparing paediatric- and adult-onset linear morphoea in a large tertiary-referral scleroderma centreAmanda M Saracino, Christina George, Svetlana I Nihtyanova, et al.
International Journal of Molecular Sciences|April 28, 2023
Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in RatsGöran Tornling, Rohit Batta, Dan Salvail, et al.
BMJ Case Reports|March 12, 2018
The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toesKiran Dhaliwal, Michelle Griffin, Christopher P Denton, et al.
Pageof 61